Table 2.
Participant characteristics in quartiles of MR-proANP levels
| African Americans |
Non-Hispanic whites |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Quartiles of MR-proANP (pmol/L) | Quartiles of MR-proANP (pmol/L) | |||||||||
| I | II | III | IV | I | II | III | IV | |||
| <44 | 44–62 | 62–93 | >93 | P trend | <44 | 44–63 | 63–95 | >95 | P trend | |
| Age, years | 60.5 | 63.9 | 65.6 | 69.2 | <.0001 | 56.5 | 58.8 | 62.3 | 66.7 | <.0001 |
| Women, n (%) | 177 (69) | 190 (73) | 196 (76) | 187 (72) | 0.34 | 104 (47) | 110 (50) | 133 (61) | 143 (64) | 0.0003 |
| BMI, kg/m² | 32.9 | 31.8 | 31.5 | 31.5 | 0.043 | 32.0 | 31.8 | 30.6 | 31.3 | 0.11 |
| Total cholesterol, mg/dL | 198.4 | 199.1 | 203.1 | 205.0 | 0.22 | 196.3 | 196.6 | 200.0 | 193.6 | 0.27 |
| HDL cholesterol, mg/dL | 55.0 | 55.1 | 60.0 | 60.4 | <.0001 | 48.8 | 47.8 | 52.6 | 54.0 | <.0001 |
| Plasma glucose level, mg/dL | 117.6 | 115.3 | 112.1 | 118.0 | 0.055 | 110.3 | 107.8 | 104.2 | 109.7 | 0.077 |
| SBP, mm Hg | 136.1 | 140.8 | 143.5 | 148.6 | <.0001 | 129.4 | 134.9 | 137.3 | 139.5 | <.0001 |
| DBP, mm Hg | 80.6 | 80.0 | 79.6 | 79.4 | 0.63 | 76.1 | 75.8 | 75.1 | 71.4 | <.0001 |
| Pulse pressure, mm Hg | 55.5 | 60.8 | 63.9 | 69.3 | <.0001 | 53.3 | 59.1 | 62.3 | 68.1 | <.0001 |
| Hypertension severity score | 2.31 | 2.36 | 2.36 | 2.81 | <.0001 | 1.84 | 2.0 | 2.11 | 2.30 | <.0001 |
| Heart rate, bpm | 71 | 67 | 65 | 64 | <.0001 | 70 | 66 | 62 | 62 | <.0001 |
| Serum creatinine, mg/dL | 0.82 | 0.86 | 0.88 | 1.05 | <.0001 | 0.87 | 0.89 | 0.90 | 0.97 | 0.0003 |
| eGFR, ml/min | 110.0 | 101.4 | 97.3 | 81.2 | <.0001 | 89.4 | 87.2 | 82.1 | 74.7 | <.0001 |
| Smoking, n (%) | 109 (42) | 98 (38) | 99 (38) | 112 (43) | 0.47 | 112 (51) | 101 (46) | 102 (47) | 115 (52) | 0.52 |
| Diabetes, n (%) | 90 (35) | 88 (34) | 75 (29) | 95 (37) | 0.27 | 41 (19) | 39 (18) | 29 (13) | 50 (23) | 0.090 |
| History of MI/stroke, n (%) | 19 (7) | 31 (12) | 27 (10) | 61(24) | <.0001 | 27 (12) | 21 (10) | 27 (12) | 47 (21) | 0.0037 |
| Statin, n (%) | 55 (21) | 52 (20) | 46 (18) | 71 (28) | 0.051 | 78 (35) | 78 (35) | 75 (34) | 76 (34) | 0.99 |
| Aspirin, n (%) | 86 (33) | 90 (35) | 94 (36) | 101 (40) | 0.56 | 96 (44) | 98 (45) | 107 (49) | 131 (59) | 0.0042 |
| Beta-blockers, n (%) | 29 (11) | 40 (15) | 57 (22) | 86 (33) | <.0001 | 56 (25) | 77 (35) | 101 (46) | 140 (63) | <.0001 |
| Calcium-channel blocker, n (%) | 90 (35) | 101 (39) | 84 (32) | 91 (35) | 0.48 | 40 (18) | 38 (17) | 39 (18) | 58 (26) | 0.061 |
| Diuretic, n (%) | 152 (59) | 139 (54) | 132 (51) | 162 (63) | 0.031 | 113 (51) | 107 (49) | 114 (52) | 111 (50) | 0.88 |
| RAAS inhibitor, n (%) | 141 (55) | 123 (47) | 112 (43) | 130 (50) | 0.066 | 115 (52) | 107 (49) | 98 (45) | 99 (45) | 0.33 |
BMI, body mean index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; BMI, body mean index; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system; MR-proANP, midregional pro-atrial natriuretic peptide.